← All trials
NCT06801002
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 17, 2025
- Primary completion
- Feb 15, 2027
- Completion date
- Feb 15, 2028
- First posted
- Jan 30, 2025
- Last posted
- Oct 14, 2025
- Enrollment
- 25
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jabez Bioscience, IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.